ProMIS Neurosciences Inc. - Common Shares (PMN)

3.3300
+0.2000 (6.39%)
NASDAQ · Last Trade: Nov 19th, 1:33 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close3.130
Open3.210
Bid3.220
Ask3.380
Day's Range3.020 - 3.390
52 Week Range2.780 - 27.40
Volume143,240
Market Cap108.86M
PE Ratio (TTM)-0.5155
EPS (TTM)-6.5
Dividend & YieldN/A (N/A)
1 Month Average Volume381,294

Chart

About ProMIS Neurosciences Inc. - Common Shares (PMN)

ProMIS Neurosciences Inc. is a biotechnology company focused on developing innovative therapeutic solutions for neurodegenerative diseases, particularly those associated with misfolded proteins such as Alzheimer’s disease. The company utilizes its proprietary protein misfolding technology to create novel antibodies that target specific disease-causing proteins, aiming to improve outcomes for patients suffering from these debilitating conditions. Through its research efforts, ProMIS seeks to advance the understanding of neurodegeneration and provide effective treatments that may alter the course of these diseases. Read More

News & Press Releases

ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix
By ProMIS Neurosciences Inc. · Via GlobeNewswire · November 17, 2026
ProMIS (PMN) Q3 2026 Earnings Call Transcriptfool.com
Patient visits wrap up as PMN310's 12-month topline readout approaches.
Via The Motley Fool · November 13, 2026
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
Cambridge, Massachusetts, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2026, and provided a corporate update.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · November 12, 2026
Nasdaq Unusual Volume Movers: SDA, CIIT and BDMD in Recent Sessionchartmill.com
Via Chartmill · November 6, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences in November
CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming November 2026 conferences. Presentations and fireside chats will be delivered by Neil Warma, President and Chief Executive Officer. Members of the Company’s leadership team will be available for one-on-one meetings at the conferences.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · November 5, 2026
Nasdaq Unusual-Volume Movers for Nov. 3, 2026chartmill.com
Via Chartmill · November 3, 2026
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
Company to host investor conference call and webcast at 4:30 p.m. ET.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · November 3, 2026
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy
By ProMIS Neurosciences Inc. · Via GlobeNewswire · October 6, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · September 1, 2026
Promis Neurosciences Q2 Earnings Call Highlightsmarketbeat.com
Promis Neurosciences (NASDAQ:PMN) reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer’s disease. President and Chief Executive Officer Neil Warma said the company is using i
Via MarketBeat · August 13, 2026
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga.com
On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Via Benzinga · August 13, 2026
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · August 13, 2026
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Company to host investor conference call and webcast at 4:30 p.m. ET.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · August 3, 2026
Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Datamarketbeat.com
Promis Neurosciences (NASDAQ:PMN) reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer’s disease and early Alzheimer’s
Via MarketBeat · July 28, 2026
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
No ARIA-E observed across all genotypes, including APOE4 homozygotes
By ProMIS Neurosciences Inc. · Via GlobeNewswire · July 28, 2026
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares increased by
Via Benzinga · July 27, 2026
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion Leaders (KOLs) Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor Emeritus, University of California, San Francisco. They will join company leadership to discuss the Company's six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in patients with early Alzheimer's disease (AD). The analysis will focus on blinded aggregate safety data and overall trends in select biomarkers across study participants.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · July 27, 2026
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers
By ProMIS Neurosciences Inc. · Via GlobeNewswire · July 14, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences in June
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · May 28, 2026
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · May 12, 2026
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027
By ProMIS Neurosciences Inc. · Via GlobeNewswire · March 25, 2026
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer’s & Parkinson’s Diseases Conference (AD/PD™ 2026), being held March 17–21, 2026 in Copenhagen, Denmark.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · March 18, 2026
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12th, 2026 in New York, NY.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · February 4, 2026
There are notable gap-ups and gap-downs in today's session.chartmill.com
Via Chartmill · January 30, 2026
Which stocks are moving before the opening bell on Friday?chartmill.com
Via Chartmill · January 30, 2026